A three-dimensional organoid culture system derived from human glioblastomas recapitulates the hypoxic gradients and cancer stem cell heterogeneity of tumors found in vivo

Cancer Research

Volumn 76, Issue 8, 2016, Pages 2465-2477

  Hubert, Christopher G ^a   Rivera, Maricruz ^a   Spangler, Lisa C ^a   Wu, Qiulian ^a   Mack, Stephen C ^a   Prager, Briana C ^a   Couce, Marta ^b   McLendon, Roger E ^c   Sloan, Andrew E ^d   Rich, Jeremy N ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; OLIGODENDROCYTE TRANSCRIPTION FACTOR 2; TLX PROTEIN; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN METASTASIS; CANCER MODEL; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; CANCER TRANSPLANTATION; CELL AGING; CELL CULTURE TECHNIQUE; CELL EXPANSION; CELL GROWTH; CELL HETEROGENEITY; CELL HYPOXIA; CONTROLLED STUDY; GENETIC ENGINEERING; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IN VIVO STUDY; MOUSE; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; PRIORITY JOURNAL; RADIOSENSITIVITY; TUMOR INVASION; XENOGRAFT; ANIMAL; BRAIN TUMOR; CYTOPLASM; PATHOLOGY;

ANIMALS; BRAIN NEOPLASMS; CELL HYPOXIA; GLIOBLASTOMA; HETEROGRAFTS; HUMANS; MICE; NEOPLASTIC STEM CELLS; ORGANOIDS;

EID: 84969599540     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-2402     Document Type: Article

References (47)

1. Stupp R, HegiME,Mason WP, van den BentMJ, TaphoornMJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study:5-yearanalysisof theEORTC-NCICtrial.LancetOncol2009;10:459-66.
2. Lathia JD, Heddleston JM, Venere M, Rich JN. Deadly teamwork: Neural cancer stem cells and the tumor microenvironment. Cell Stem Cell 2011;8:482-5.
3. Meyer M, Reimand J, Lan X, Head R, Zhu X, Kushida M, et al. Single cellderived clonal analysis of human glioblastoma links functional and genomic heterogeneity. Proc Natl Acad Sci U S A 2015;112:851-6.
4. Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM,WakimotoH, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 2014;344:1396-401.
5. Vescovi AL, Galli R, Reynolds BA. Brain tumour stem cells. Nat Rev 2006; 6:425-36.
6. Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S, et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 2004;64:7011-21.
7. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature 2004;432: 396-401.
8. Hemmati HD, Nakano I, Lazareff JA,Masterman-Smith M,Geschwind DH, Bronner-Fraser M, et al. Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci U S A 2003;100:15178-83.
9. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444:756-60.
10. Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007;11:69-82.
11. Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S, et al. Hypoxiainducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 2009;15:501-13.
12. Seidel S, Garvalov BK, Wirta V, von Stechow L, Schanzer A, Meletis K, et al. A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha. Brain 2010;133:983-95.
13. Bar EE, Lin A, Mahairaki V, Matsui W, Eberhart CG. Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheres. Am J Pathol 2010;177:1491-502.
14. Yan K, Wu Q, Yan DH, Lee CH, Rahim N, Tritschler I, et al. Glioma cancer stem cells secrete Gremlin1 to promote their maintenance within the tumor hierarchy. Genes Dev 2014;28:1085-100.
15. Charles N, Ozawa T, Squatrito M, Bleau AM, Brennan CW, Hambardzumyan D, et al. Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells. Cell Stem Cell 2010;6:141-52.
16. Zhu TS, Costello MA, Talsma CE, Flack CG, Crowley JG, Hamm LL, et al. Endothelial cells create a stem cell niche in glioblastoma by providing NOTCH ligands that nurture self-renewal of cancer stem-like cells. Cancer Res 2011;71:6061-72.
17. Wang H, Lathia JD, Wu Q, Wang J, Li Z, Heddleston JM, et al. Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth. Stem Cells (Dayton, Ohio) 2009;27:2393-404.
18. Bao S, Wu Q, Sathornsumetee S, Hao Y, Li Z, Hjelmeland AB, et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 2006;66:7843-8.
19. Cheng L, Huang Z, Zhou W, Wu Q, Donnola S, Liu JK, et al. Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell 2013;153:139-52.
20. Becher OJ, Holland EC. Genetically engineered models have advantages over xenografts for preclinical studies. Cancer Res 2006;66:3355-8, discussion 58-9.
21. Shamir ER, Ewald AJ. Three-dimensional organotypic culture: Experimental models of mammalian biology and disease. Nat Rev Mol Cell Biol 2014;15:647-64.
22. Boj SF, Hwang CI, Baker LA, Chio II, Engle DD, Corbo V, et al. Organoid models of human and mouse ductal pancreatic cancer. Cell 2015;160: 324-38.
23. McCracken KW, Cata EM, Crawford CM, Sinagoga KL, Schumacher M, Rockich BE, et al. Modelling human development and disease in pluripotent stem-cell-derived gastric organoids. Nature 2014;516: 400-4.
24. Smith SJ, Wilson M, Ward JH, Rahman CV, Peet AC, Macarthur DC, et al. Recapitulation of tumor heterogeneity and molecular signatures in a 3D brain cancer model with decreased sensitivity to histone deacetylase inhibition. PLoS One 2012;7:e52335.
25. Lancaster MA, Knoblich JA. Generation of cerebral organoids from human pluripotent stem cells. Nat Protoc 2014;9:2329-40.
26. Lancaster MA, Renner M, Martin CA, Wenzel D, Bicknell LS, Hurles ME, et al. Cerebral organoids model human brain development and microcephaly. Nature 2013;501:373-9.
27. Gao D, Vela I, Sboner A, Iaquinta PJ, Karthaus WR, Gopalan A, et al. Organoid cultures derived from patients with advanced prostate cancer. Cell 2014;159:176-87.
28. Karthaus WR, Iaquinta PJ, Drost J, Gracanin A, van Boxtel R, Wongvipat J, et al. Identification of multipotent luminal progenitor cells in human prostate organoid cultures. Cell 2014;159:163-75.
29. Sato T, Vries RG, Snippert HJ, van de WeteringM, Barker N, StangeDE, et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 2009;459:262-5.
30. Mohyeldin A, Garzon-Muvdi T, Quinones-Hinojosa A.Oxygen in stem cell biology: a critical component of the stem cell niche. Cell Stem Cell 2010; 7:150-61.
31. Joo KM, Kim J, Jin J, Kim M, Seol HJ, Muradov J, et al. Patient-specific orthotopic glioblastoma xenograft models recapitulate the histopathology and biology of human glioblastomas in situ. Cell Rep 2013;3:260-73.
32. Cloughesy TF, Cavenee WK, Mischel PS. Glioblastoma: from molecular pathology to targeted treatment. Annu Rev Pathol 2014;9:1-25.
33. Flavahan WA, Wu Q, Hitomi M, Rahim N, Kim Y, Sloan AE, et al. Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake. Nat Neurosci 2013;16:1373-82.
34. Young RA. Control of the embryonic stem cell state. Cell 2011;144: 940-54.
35. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126:663-76.
36. Suva ML, Rheinbay E, Gillespie SM, Patel AP, Wakimoto H, Rabkin SD, et al. Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells. Cell 2014;157:580-94.
37. de la Rocha AM, Sampron N, Alonso MM, Matheu A. Role of SOX family of transcription factors in central nervous system tumors. Am J Cancer Res 2014;4:312-24.
38. Potter C, Harris AL. Hypoxia inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy target. Cell Cycle (Georgetown, Tex 2004;3:164-7.
39. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A 1995;92:9363-7.
40. Qu Q, Sun G, Li W, Yang S, Ye P, Zhao C, et al. Orphan nuclear receptor TLX activates Wnt/beta-catenin signalling to stimulate neural stem cell proliferation and self-renewal. Nat Cell Biol 2010;12:31-40; sup pp 1-9.
41. Zou Y, Niu W,Qin S, Downes M, Burns DK, Zhang CL. The nuclear receptor TLX is required for gliomagenesis within the adult neurogenic niche. Mol Cell Biol 2012;32:4811-20.
42. Liu HK, Wang Y, Belz T, Bock D, Takacs A, Radlwimmer B, et al. The nuclear receptor tailless induces long-term neural stem cell expansion and brain tumor initiation. Genes Dev 2010;24:683-95.
43. Zhu Z, Khan MA, Weiler M, Blaes J, Jestaedt L, Geibert M, et al. Targeting self-renewal in high-grade brain tumors leads to loss of brain tumor stem cells and prolonged survival. Cell Stem Cell 2014;15:185-98.
44. Shimozaki K, Zhang CL, Suh H, Denli AM, Evans RM, Gage FH. SRY-boxcontaining gene 2 regulation of nuclear receptor tailless (Tlx) transcription in adult neural stem cells. J Biol Chem 2012;287:5969-78.
45. Ligon KL, Huillard E, Mehta S, Kesari S, Liu H, Alberta JA, et al. Olig2- regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma. Neuron 2007;53:503-17.
46. Mehta S, Huillard E, Kesari S, Maire CL, Golebiowski D, Harrington EP, et al. The central nervous system-restricted transcription factor Olig2 opposes p53 responses to genotoxic damage in neural progenitors and malignant glioma. Cancer Cell 2011;19:359-71.
47. Matano M, Date S, Shimokawa M, Takano A, Fujii M, Ohta Y, et al. Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids. Nat Med 2015;21:256-62.